{
    "eid": "2-s2.0-85068412382",
    "title": "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia",
    "cover-date": "2019-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "adalimumab",
        "biosimilar",
        "Crohn's disease",
        "inflammatory bowel disease",
        "infliximab",
        "ulcerative colitis"
    ],
    "authors": [
        "Choon Jin Ooi",
        "Ida Hilmi",
        "Rupa Banerjee",
        "Sai Wei Chuah",
        "Siew Chien Ng",
        "Shu Chen Wei",
        "Govind K. Makharia",
        "Pises Pisespongsa",
        "Min Hu Chen",
        "Zhi Hua Ran",
        "Byong Duk Ye",
        "Dong Il Park",
        "Khoon Lin Ling",
        "David Ong",
        "Vineet Ahuja",
        "Khean Lee Goh",
        "Jose Sollano",
        "Wee Chian Lim",
        "Wai Keung Leung",
        "Raja Affendi Raja Ali",
        "Deng Chyang Wu",
        "Evan Ong",
        "Nazri Mustaffa",
        "Julajak Limsrivilai",
        "Tadakazu Hisamatsu",
        "Suk Kyun Yang",
        "Qin Ouyang",
        "Richard Geary",
        "Janaka H. De Silva",
        "Rungsun Rerknimitr",
        "Marcellus Simadibrata",
        "Murdani Abdullah",
        "Rupert W.L. Leong"
    ],
    "citedby-count": 32,
    "ref-count": 182,
    "ref-list": [
        "Asia Pacific consensus statements on Crohn's disease. Part 1: definition, diagnosis, and epidemiology: (Asia Pacific Crohn's disease consensus\u2014part 1)",
        "Asia\u2013Pacific consensus statements on Crohn's disease. Part 2: management",
        "The Delphi method: techniques and applications",
        "The period health examination",
        "Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease",
        "Current directions in IBD therapy: what goals are feasible with biological modifiers?",
        "Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease",
        "Adalimumab induces deep remission in patients with Crohn's disease",
        "Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial",
        "Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial",
        "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial",
        "Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial",
        "Certolizumab pegol for the treatment of Crohn's disease",
        "Maintenance therapy with certolizumab pegol for Crohn's disease",
        "The Italian Society of Gastroenterology (SIGE) and the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease",
        "Vedolizumab as induction and maintenance therapy for Crohn's disease",
        "Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed",
        "3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management",
        "Ustekinumab induction and maintenance therapy in refractory Crohn's disease",
        "Select a suitable treatment strategy for Crohn's disease: step-up or top-down",
        "Top-down therapy for IBD: rationale and requisite evidence",
        "Risk of tuberculosis with anti-tumor necrosis factor-\u03b1 therapy: substantially higher number of patients at risk in Asia",
        "Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries",
        "What is the optimal therapy for Crohn's disease: step-up or top-down?",
        "Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach",
        "Predictors of Crohn's disease",
        "Risk of early surgery for Crohn's disease: implications for early treatment strategies",
        "Recommendations for identifying Crohn's disease patients with poor prognosis",
        "Epidemiology, natural history, and risk stratification of Crohn's disease",
        "The role of smoking in Crohn's disease as defined by clinical variables",
        "Crohn's disease evaluation and treatment: clinical decision tool",
        "Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors",
        "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial",
        "Infliximab, azathioprine, or combination therapy for Crohn's disease",
        "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis",
        "Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials",
        "Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy",
        "Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease",
        "Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease",
        "Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease",
        "Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial",
        "Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial",
        "Combination immunosuppression in IBD",
        "Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease",
        "Infliximab maintenance therapy for fistulizing Crohn's disease",
        "Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Vol. 149",
        "Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped",
        "De-escalation of therapy in inflammatory bowel disease",
        "Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease",
        "Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease\u2014a nested case\u2013control study",
        "Tumor necrosis factor-\u03b1 antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis",
        "Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2",
        "Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease",
        "Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial",
        "Infliximab for induction and maintenance therapy for ulcerative colitis",
        "Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis",
        "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis",
        "Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis",
        "Vedolizumab as induction and maintenance therapy for ulcerative colitis",
        "Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study",
        "Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review",
        "Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial",
        "Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial",
        "Review article: acute severe ulcerative colitis\u2014evidence-based consensus statements",
        "Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease",
        "Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort",
        "The safety of vedolizumab for ulcerative colitis and Crohn's disease",
        "One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study",
        "Vedolizumab as induction and maintenance therapy for Crohn's disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy",
        "Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies",
        "The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection",
        "Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)",
        "Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial",
        "Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial",
        "Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis",
        "Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment",
        "Biosimilars in the treatment of inflammatory bowel disease: supporting evidence in 2017",
        "The experience with biosimilars of infliximab in inflammatory bowel disease",
        "Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes",
        "The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar",
        "Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study",
        "Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea",
        "Progress with infliximab biosimilars for inflammatory bowel disease",
        "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target",
        "Converging goals of treatment of inflammatory bowel disease from clinical trials and practice",
        "Current best practice for disease activity assessment in IBD",
        "Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study",
        "Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease",
        "A simple index of Crohn's-disease activity",
        "Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial",
        "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis",
        "Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort",
        "Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease",
        "Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease",
        "Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis",
        "Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease",
        "Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial",
        "Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease",
        "Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial",
        "Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF\u03b1 blocking agents",
        "Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease",
        "Faecal calprotectin assay after induction with anti-tumour necrosis factor \u03b1 agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year",
        "C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study",
        "Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines",
        "Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy",
        "A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy",
        "A prospective 12-week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy",
        "Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn's disease using biomarkers, capsule endoscopy, and imaging",
        "Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease",
        "Mucosal healing in Crohn's disease\u2014are we reaching as far as possible with capsule endoscopy?",
        "Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn's disease",
        "Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn's disease: systematic review and meta-analysis",
        "Validation of the Lewis score for the evaluation of small-bowel Crohn's disease activity",
        "Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study",
        "Clinical practice guidelines for the use of video capsule endoscopy",
        "The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease",
        "Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review",
        "Safety, reliability and limitations of the given patency capsule in patients at risk of capsule retention: a 3-year technical review",
        "Capsule retentions and incomplete capsule endoscopy examinations: an analysis of 2300 examinations",
        "PillCam colon capsule endoscopy versus conventional colonoscopy for the detection of severity and extent of ulcerative colitis",
        "Applicability of second-generation colon capsule endoscope to ulcerative colitis: a clinical feasibility study",
        "Colon capsule endoscopy versus standard colonoscopy in assessing disease activity of ulcerative colitis: a prospective trial",
        "The use of Pillcam Colon in assessing mucosal inflammation in ulcerative colitis: a multicenter study",
        "Video capsule endoscopy in inflammatory bowel disease",
        "Outcomes 7 years after infliximab withdrawal for patients with Crohn's disease in sustained remission",
        "European Crohn's and Colitis Organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease",
        "Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse",
        "Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease",
        "Randomised controlled trial of azathioprine withdrawal in ulcerative colitis",
        "A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine",
        "Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission",
        "When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel",
        "Impact on life expectancy of withdrawing thiopurines in patients with Crohn's disease in sustained clinical remission: a lifetime risk\u2013benefit analysis",
        "Screening of TPMT deficiency by phenotyping and genotyping: a retrospective study among 1,500 IBD patients in France",
        "Optimizing thiopurine therapy in inflammatory bowel disease",
        "Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore",
        "A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia",
        "Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease",
        "Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?",
        "NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity",
        "Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia",
        "Association of NUDT15 c.415C>T allele and thiopurine-induced leukocytopenia in Asians: a systematic review and meta-analysis",
        "Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease",
        "Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease",
        "Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis",
        "A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease",
        "The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease",
        "Factors associated with short- and long-term outcomes of therapy for Crohn's disease",
        "Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease",
        "Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease",
        "Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases",
        "Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease",
        "Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases",
        "Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease",
        "Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases",
        "Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab",
        "Antibody response to infliximab and its impact on pharmacokinetics can be transient",
        "The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management",
        "A controlled double blind study of azathioprine in the management of Crohn's disease",
        "Treatment of Crohn's disease with 6-mercaptopurine",
        "Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease",
        "Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis",
        "Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease",
        "Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease",
        "Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease",
        "Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease",
        "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease",
        "Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy",
        "Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity",
        "Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease",
        "Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease",
        "Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy",
        "Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases",
        "Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis",
        "Extrapulmonary tuberculosis: are statistical reports accurate?",
        "The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan",
        "Seminar report from the 2014 Taiwan Society of Inflammatory Bowel Disease (TSIBD) Spring Forum (May 24th, 2014): Crohn's disease versus intestinal tuberculosis infection",
        "Latent tuberculosis infection in the United States",
        "Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist",
        "Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management",
        "How should we manage latent tuberculosis infection in patients receiving anti-TNF-\u03b1 drugs: literature review",
        "Latent tuberculosis treatment results in patients that taken TNF-alpha blockers at Ankara Numune Training and Research Hospital Chest Diseases Clinic for last 8 years (2006\u20132013)"
    ],
    "affiliation": [
        {
            "affiliation-city": "Seoul",
            "@id": "60006240",
            "affilname": "University of Ulsan College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60095034",
            "affilname": "Duke-NUS Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60095034",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60082819",
            "affilname": "Shanghai Jiao Tong University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082819",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Chengdu",
            "@id": "60073509",
            "affilname": "West China School of Medicine/West China Hospital of Sichuan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073509",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Manila",
            "@id": "60071488",
            "affilname": "University of Santo Tomas, Manila",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071488",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Kelaniya",
            "@id": "60071104",
            "affilname": "University of Kelaniya",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071104",
            "affiliation-country": "Sri Lanka"
        },
        {
            "affiliation-city": "Central Jakarta",
            "@id": "60069378",
            "affilname": "Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069378",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Depok",
            "@id": "60069377",
            "affilname": "Universitas Indonesia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069377",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031325",
            "affilname": "National University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031325",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Sydney",
            "@id": "60029482",
            "affilname": "Concord Repatriation General Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029482",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60029157",
            "affilname": "Universiti Malaya",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029157",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60021182",
            "affilname": "Sun Yat-Sen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021182",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Mitaka",
            "@id": "60019092",
            "affilname": "Kyorin University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019092",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60017958",
            "affilname": "Singapore General Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017958",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Suwon",
            "@id": "60016329",
            "affilname": "SKKU School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016329",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Hyderabad",
            "@id": "60016172",
            "affilname": "Asian Institute of Gastroenterology India",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016172",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60013665",
            "affilname": "University of Malaya Medical Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013665",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Kaohsiung",
            "@id": "60012256",
            "affilname": "Kaohsiung Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012256",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "New Delhi",
            "@id": "60009790",
            "affilname": "All India Institute of Medical Sciences, New Delhi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009790",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60007189",
            "affilname": "Gleneagles Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007189",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60006541",
            "affilname": "The University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006541",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60002798",
            "affilname": "Chinese University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60002481",
            "affilname": "Tan Tock Seng Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002481",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Christchurch",
            "@id": "60002143",
            "affilname": "University of Otago, Christchurch",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002143",
            "affiliation-country": "New Zealand"
        },
        {
            "affiliation-city": "Bangi",
            "@id": "60001821",
            "affilname": "Universiti Kebangsaan Malaysia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001821",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Minden-Pulau Pinang",
            "@id": "123957467",
            "affilname": "Universiti Sains",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123957467",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "122799584",
            "affilname": "Bumrungrad International University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122799584",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}